30. September 2010 17:30
GlaxoSmithKline has been forced to abandon trials of its genital herpes vaccine, after it was found not to prevent the disease.
This is big pharma’s third product disappointment in the last few days, after prostate cancer therapies manufactured by Pfizer and AZ also failed to meet their primary endpoints.
Further investigation into the product, Simplirix (Herpes Simplex Vaccine), was decided against after the results of an eight-year phase III trial, conducted with the US National Institute of Allergy and Infectious Diseases (NIAID), showed the vaccine failed to prevent genital herpes.
Gary Dubin, Vice President and Director, Late Clinical Development at GlaxoSmithKline Biologicals said: “We would like to express our gratitude towards our partner NIAID for their proactive collaboration and substantial contribution in the program and the volunteers for their participation in the study.”